$NKTX 8-K/A SEC Filings

Filed On	Filing
16 Aug 2024	8-K/A: Results of Operations and Financial Condition Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitis

Comments